コンテンツへスキップ
Merck
  • A prospective cohort study of the effect of depot medroxyprogesterone acetate on detection of plasma and cervical HIV-1 in women initiating and continuing antiretroviral therapy.

A prospective cohort study of the effect of depot medroxyprogesterone acetate on detection of plasma and cervical HIV-1 in women initiating and continuing antiretroviral therapy.

Journal of acquired immune deficiency syndromes (1999) (2014-05-07)
Summer Day, Susan M Graham, Linnet N Masese, Barbra A Richardson, James N Kiarie, Walter Jaoko, Kishorchandra Mandaliya, Vrasha Chohan, Julie Overbaugh, R Scott McClelland
要旨

Depot medroxyprogesterone acetate (DMPA) use among HIV-1-infected women may increase transmission by increasing plasma and genital HIV-1 RNA shedding. We investigated associations between DMPA use and HIV-1 RNA in plasma and cervical secretions. One hundred two women initiated antiretroviral therapy, contributing 925 follow-up visits over a median of 34 months. Compared with visits with no hormonal contraception exposure, DMPA exposure did not increase detection of plasma (adjusted odds ratio: 0.81, 95% confidence interval: 0.47 to 1.39) or cervical HIV-1 RNA (adjusted odds ratio: 1.41, 95% confidence interval: 0.54 to 3.67). Our results suggest that DMPA is unlikely to increase infectivity in HIV-positive women who are adherent to effective antiretroviral therapy.

材料
製品番号
ブランド
製品内容

Sigma-Aldrich
メドロキシプロゲステロン17-アセタート, ≥97% (HPLC)
USP
メドロキシプロゲステロン17-アセタート, United States Pharmacopeia (USP) Reference Standard
Supelco
メドロキシプロゲステロン17-アセタート, VETRANAL®, analytical standard
メドロキシプロゲステロン17-アセタート, European Pharmacopoeia (EP) Reference Standard
メドロキシプロゲステロン17-アセタート, European Pharmacopoeia (EP) Reference Standard